A demonstration area for type 2 diabetes prevention in Barranquilla and Juan Mina (Colombia)

Medicine (United States)

Volumn 97, Issue 1, 2018, Pages

  Acosta, Tania ^a   Barengo, Noël C ^b   Arrieta, Astrid ^c   Ricaurte, Carlos ^c   Tuomilehto, Jaakko O ^d,e,f,g,h  

^a UNIVERSIDAD DEL NORTE   (Colombia)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c Centro de Investigation Sanitaria   (Colombia)

^d DASMAN DIABETES INSTITUTE   (Kuwait)

^e DANUBE UNIVERSITY KREMS   (Austria)

^f National Institute for Health and Welfare   (United States)

^g UNIVERSITY OF HELSINKI   (Finland)

^h KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Colombia; nutrition; physical activity; primary healthcare

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; COLOMBIA; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; AGED;

ADULT; AGED; BLOOD GLUCOSE; COLOMBIA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 85041483425     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000009285     Document Type: Article

References (42)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
2. World Health OrganizationObesity: Preventing andManaging the Global Epidemic. Report of aWHOConsultation. WHOTechnicalReport Series. 2000;World Health Organization, Geneva, Switzerland:894.
3. The DECODE Study Group on behalf of the European Diabetes Epidemiology GroupGlucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.
4. Knowler W, Narayan K, Hanson R, et al. Perspectives in diabetes. Preventing non-insulin-dependent diabetes. Diabetes 1995;44:483-8.
5. The DECODA Study GroupAge-and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003;26:1770-80.
6. The DECODE Study GroupAge-and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003;26:61-9.
7. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
8. The DECODE Study GroupGlucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
9. Qiao Q, Jousilahti P, Eriksson J, et al. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 2003;26:2910-4.
10. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
11. Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-97.
12. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.
13. Tuomilehto J, Lindström J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
14. Adams R, Hebert CJ, Mcvey L, et al. Implementation of the YMCA Diabetes Prevention Program throughout an Integrated Health System: a Translational Study. Perm J 2016;20:82-6.
15. Costa B, Barrio F, Cabré JJ, et al. DE-PLAN-CAT Research Group-Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. Diabetologia 2012;55:1319-28.
16. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26:725-31.
17. Saaristo T, Peltonen M, Lindström J, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res 2005;2:67-72.
18. Franciosi M, De Berardis G, Rossi MC, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care 2005;28:1187-94.
19. Makrilakis K, Liatis S, Grammatikou S, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab 2011;37:144-51.
20. Schwarz PE, Lindström J, Kissimova-Scarbeck K, et al. DE-PLAN projectThe European Perspective of Type 2Diabetes Prevention: diabetes in Europe-prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes 2008;116:167-72.
21. Costa B, Barrio F, Cabré JJ, et al. Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. Diabetologia 2012;55:1319-28.
22. Rydén L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD)Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
23. Barengo NC, Tamayo DC, Tono T, et al. A Colombian diabetes risk score for detecting undiagnosed diabetes and impaired glucose regulation. Prim Care Diabetes 2017;11:86-93.
24. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med 2007;24:451-63.
25. Craig CL, Marshall AL, SjöströmM, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381-95.
26. Ekelund U, Sepp H, Brage S, et al. Criterion-related validity of the last 7-day, short form of the International Physical Activity Questionnaire in Swedish adults. Public Health Nutr 2006;9:258-65.
27. Bonita R, deCourten M, Dwyer T, et al. Surveillance of Risk Factors for Noncommunicable Diseases: The WHO STEP Wise Approach. World Health Organization, Geneva, Switzerland:2002.
28. WHO. Chronic diseases and health promotion. STEPwise approach to chronic disease risk factor surveillance (STEPS); 2013. [Last cited on 2013 Apr 15]. Available at: http://www.who.int/chp/steps/riskfactor/en/index.html. Accessed March 15, 2017.
29. Hu G, Barengo NC, Tuomilehto J, et al. Relationship of physical activity and body mass index to the risk of hypertension: a prospective study in Finland. Hypertension 2004;43:25-30.
30. Hu G, Qiao Q, Silventoinen K, et al. Occupational, commuting, and leisure-time physical activity in relation to risk for type 2 diabetes in middle-aged Finnish men and women. Diabetologia 2003;46:322-9.
31. Keys A. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Harvard University Press, Cambridge, MA:1980.
32. Albanes D, Conway JM, Taylor PR, et al. Validation and comparison of eight physical activity questionnaires. Epidemiology 1990;1:65-71.
33. Salonen JT, Slater JS, Tuomilehto J, et al. Leisure time and occupational physical activity: risk of death from ischemic heart disease. Am J Epidemiol 1988;127:87-94.
34. WHO ConsultationDefinition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. 1999;World Health Organisation, Geneva:Report No.: Report No 99.2.
35. American Diabetes Association Position StatementDiagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:S62-9.
36. Davies M, Day J. Screening for noninsulin dependent diabetes mellitus (NIDDM): how often should it be done? J Med Screen 1994;1:78-81.
37. Barengo NC, Acosta T, Arrieta A, et al. Screening for people with glucose metabolism disorders within the framework of the DEMOJUAN project (DEMOnstration area for primary prevention of type 2 diabetes, JUAN Mina and Barranquilla, Colombia). Diabetes Metab Res Rev 2013;doi: 10.1002/dmrr.2462.
38. Penn L, White M, Oldroyd J, et al. Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health 2009;9:342.
39. Facchinetti A, Sparacino G, Guerra S, et al. Real-time improvement of continuous glucose monitoring accuracy: the smart sensor concept. Diabetes Care 2013;36:793-800.
40. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabeteswith lifestyle intervention or metformin. New Engl J Med 2002;346:393-403.
41. Mensink M, Corpeleijn E, Feskens EJM, et al. Study on lifestyleintervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Res Clin Pract 2003;61:49-58.
42. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention. A Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67:152-62.